AOD9604 5 mg
Also known as · AOD-9604 · hGH fragment 176-191
AOD9604 is a modified 15-residue fragment derived from the C-terminus of human growth hormone. Studied for lipolytic research applications.
Chemistry quick-facts
- CAS
- 221231-10-3
- Formula
- C78H123N23O23S2
- MW
- 1815.08 Da
- Length
- 15 aa
- Status
- Phase 2b obesity trial completed (did not meet primary endpoint). Marketed as a food ingredient in some jurisdictions. No therapeutic approval.
- Purity (HPLC)
- ≥ 99.0%
Mechanism of action
Proposed: direct effects on adipocyte lipolysis, independent of GH receptor signalling.
Research context
AOD9604 is a modified C-terminal fragment of hGH (residues 176-191), engineered by Metabolic Pharmaceuticals. It was studied in a Phase 2b obesity trial that did not meet its primary endpoint.
The peptide is approved as a food ingredient in some jurisdictions but has no therapeutic approval.
Published studies
A non-exhaustive list of peer-reviewed studies referenced when curating this entry. Click through to the primary source for the full text.
- Heffernan M, Summers RJ, Thorburn A, et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology.
Reconstitution
- Solvent
- Bacteriostatic water for injection (0.9% benzyl alcohol) — included with kit
- Typical volume
- 1 – 2 mL
- · Inject diluent slowly down the side of the vial onto the cake.
- · Swirl gently — do not shake.
- · Solution should be clear and colourless. Discard if not.
Storage
- Lyophilised
- −20 °C, desiccated, protected from light. Stable at 15–25 °C for up to 30 days in transit.
- Reconstituted
- 2–8 °C, original vial, consumed within 4 weeks.
- Shelf life — sealed
- 24 months from date of manufacture when stored lyophilised at −20 °C.
FAQ
Did AOD9604 reach clinical approval?+
No — the Phase 2b obesity trial did not meet its primary endpoint. The peptide is used as a preclinical research reagent and has food-ingredient approval in some jurisdictions.
This page summarises the research literature on AOD9604 5 mg for in vitro laboratory investigation only. It is not medical advice, not a treatment recommendation, and not a substitute for a qualified physician. Material is sold for analytical chemistry and cell-culture research, not for human or veterinary administration.
- ResearchMOTS-c 40 mg
MOTS-c is a 16-residue peptide encoded in the mitochondrial 12S rRNA region. Described by the Cohen lab in 2015 — studied in metabolic and exercise bi
- ResearchNAD⁺ 500 mg kit
Nicotinamide adenine dinucleotide — the coenzyme central to cellular electron-transfer, sirtuin signalling, and redox biology.
- ResearchNAD⁺ 1000 mg pen
High-dose pen format NAD⁺ — double the 500 mg vial kit, in a pre-filled pen device.
- BiomarkerTSH 4.5 mIU/L
TSH at 4.5 mIU/L sits at the top edge of most printed reference ranges (typically 0.4–4.0). What that number indicates physiologically, why "high-normal" matters, and what the research literature looks at when this pattern appears.
- BiomarkerHOMA-IR 2.5
HOMA-IR is a calculated index from fasting glucose × fasting insulin. A HOMA-IR of 2.5 sits at the threshold most metabolic research uses for early insulin resistance, often years before HbA1c shifts.
- BiomarkerFree T3 low, TSH normal
Free T3 below the reference range with a normal TSH suggests your body isn't converting T4 into the active T3 hormone efficiently. The research literature on conversion problems and what they look like.